I sat down with Julie Waras Brogren. Deputy CEO for Biotech Ascelia Pharma as part of my #ReflectionsandForecast20222023 interview series.
I asked Julie...
✺ For those who are not familiar, please give us a quick introduction to you and Ascelia Pharma. 01:05
✺ In what way is your technology innovative and how does it differ from other products on the market? 02:22
✺ What is Orviglance and what stage are you currently at with Orviglance? 05:01
✺ One word to describe 2022 and why? 05:23
✺ What were some of company's key achievements in 2022? 06:18
✺ Looking back at 2022 what challenges did you see the sector face, and developments stood out for you? Are there any trends and challenges you are noticing as an emerging biotech company? 07:54
✺ Has it been difficult to get investment for non-covid related #drugdevelopment? 09:35
✺ Is Ascelia’s #ClinicalTrials program global and was it impacted by #Covid? 10:17
✺ Are there any areas you think the industry could improve? 11:33
✺ What are your predictions for #LifeScience/ #Pharma/ #BioPharma in 2023? 12:57
✺ What developments and trends do you expect to see/predict in #orphanoncology treatments? 14:42
✺Lets look more specifically at Ascelia in 2023 and beyond. As a #biotech with a developing portfolio, where is your focus, what are your 2-3 year objectives? 17:22
✺ In terms of the future, what partnerships and collaborations would be ideal for advancing the company’s growth? 19:14
✺ Finally, what last thoughts would you like to leave viewers with for 2023? 22:09
Feel free to leave any questions or comments for Julie below.
🎞 You can WATCH the interview here https://lnkd.in/enT7WtC3
You can learn more about #AsceliaPharma at www.Ascelia.com